Dyslipidemia in patients with HIV
DOI:
https://doi.org/10.31052/1853.1180.v18.n3.11733Keywords:
Human Immunodeficiency Virus HIV – Acquired immunodeficiency syndrome. Antiretroviral therapy. DyslipidemiasAbstract
Abstract Since the introduction of highly active antiretroviral therapy (ART) in the treatment of HIV/AIDS patients, we have observed a change in the development of the disease, becoming a chronic therapeutically containable condition. The increase in survival goes together with associated diseases; cardiovascular ones have become relevant, being earlier and more severe. Dyslipidemias have a leading role in this pathology. In this work, we analyze their incidence and characteristics in HIV patients, with and without ART treatment. Lipid profile was different in the pre-treatment stage (low HDL, low total Cholesterol and normal TG) from the stage under ART (marked increase of TG and to a lesser extent of total Cholesterol and LDL), with a significant association of the use of Protease Inhibitors (PIs) and CD4 levels lower than 200/mm3.
Downloads
References
1. Vacarezza M, Vazquez R, Savio E. Alteraciones del metabolismo lipidico en pacientes infectados por VIH. Revista Medica Uruguay 2003;19: 45-52.
2. Informe de la situación nacional VIH/SIDA. Cátedra de Enfermedades Infecciosas. Julio 2012. Montevideo.
3. Neumann T, Woiwod T, Neumann A et al. Cardiovascular Risk Factors and Probability for Cardiovascular Events in HIV- Infected Patients. European Journal of Medical Research 2004; 9: 267-272.
4. Dronda, F . Riesgo vascular e infeccion por el virus de la inmunodeficiencia humana tipo 1. MED. CLIN. 01/2004;122(8):301-303.
5. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747-8.
6. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, Stoll M, Schmidt RE (1999). Impaired glucose tolerance and beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13: F63-F70.
7. Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA, Minoz A (2001) Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 15 :347- 355
8. Friis-Moller N, Weber R, D’Arminio Monforte A, El Sadr W, Reiss P, Dabis F, et al. Exposure to HAART is associated with an increased risk of myocardial infarction: the DAD study. En: Programs and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; 2003,February; Boston 2003 [abstract 130]
9. Gotto A, Assmann G, Carmena R, Davignon J, Fernandez Cruz A, Paoletti R. Manual ILIB sobre lipidos para la practica clinica. Buenos Aires: Waberly Hispanica, 1998; 130-6.
10. Summary of the Second Report of tje National Cholesterol Education Program (NCEP) Expert Pannel on Detection, Evaluation, and treatment of High Blooe Cholestyerol in Adult s (ATP-ll). JAMA 1993; 269: 3015 -23.
PUPPO D, VALIÑO J, TORALES M | Dislipemias en pacientes VIHRevista de Salud Pública, (XVIII) 3:8-14, dic 201414
11. Estrada V, Portilla J. Dyslipidemia Related to Antiretroviral Therapy. AIDS Rev.2011; 13: 49-56
12. Oh J, Hegele R. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis. 2007; 7:787-96.
13. Christeff N, Lortholary O, Casassus P, Thobie N, Dalle MT, Veyssier P, et al. Serum lipid concentration with reference to the clinical and inmunological status of HIV infected men. Ann Med Interne (Paris) 1995; 146(7): 490-5.
14. Ducobu J, Payen MC. Lipids and AIDS. Rev Med Brux 2000; 21(1): 11-7.
15. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chiismo DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor associated lipodistrophy, hyperlipidaemia and diabetes mellitus; a cohort study. Lancet 1999; 353(9170): 2093-9
16. Kotler DP. Update on metabolic and morphologic abnormalities in HIV. Medscape HIV/AIDS: 1999 Annual Update. (www.medscape.com/Medscape/HIV/Treatment Update/1999).
17. Crook MA, Mir N. Abnormal lipids and the acquired immunodeficiency syndrome: is there a problem and what should we do about it? Int J STD AIDS 1999; 10(6): 353-6.
18. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of Protease Inhibitors on Hyperglycemia, hyperlipidemia and lipodystrophy: a 5 year cohort study. Arch Intern Med 2000;160(13): 2050-6.
19. Carr A, Chuah J, Hudson J, French M, Hoy J, Law M, et al. A randomised, open label comparision of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-Infection: the OzCombo1 study. AIDS 2000; 14(9): 1171-80.
20. Carpentier A, Patterson B, Uffelman K, Salit I, Lewis G. Mechanism of highly active antiretroviral therapy-induced hyperlipidemia in HIV-infected individuals. Atherosclerosis. 2005;178:165-72.
21. Lenhard J, Croom DK, Weiel J, Winegar D. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol. 2000; 20:2625-9.
Downloads
Published
Issue
Section
License
Copyright (c) 2015 Escuela de Salud Pública y Ambiente. Facultad de Ciencias Médicas. Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License which allows the work to be copied, distributed, exhibited and interpreted as long as it is not done for commercial purposes.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) after the publication process. (See The Effect of Open Access). (See The Effect of Open Access).
How to Cite
